PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors ...Middle East

Initiation of Phase 1a/b clinical trial exploring MTD, RP2D, safety and tolerability of PMC-309 monotherapy and combination therapy with KEYTRUDA® The clinical trial aims to enroll a total of 67 patients across four institutions in Australia DAEJEON, South Korea, Jan. 23, 2024...

Hence then, the article about pharmabcine announces first patient dosed in phase 1a b clinical trial of pmc 309 in combination with keytruda pembrolizumab in patients with advanced or metastatic solid tumors was published today ( Wednesday 24/01/2024 - 05:12 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors )

Also on site :

• What channel is Kosovo v Republic of Ireland Nations League match on? UK TV coverage, live stream and kick-off time
• Nifty breakout from 23,000-23,600 range to set market trend: Sachin Gupta
• Marathon Fusion Publishes New Pathway for Scalable Production of Promising Cancer-Treatment Isotope Terbium-149